Trinity Biotech plc (TRIB)

NMS – Real vaqt narxi. Valyuta: USD

0.36

+0.01 (3.44%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

0.34

-0.02 (-5.82%)

Bozordan keyin: Jun 26, 2026, 7:56 PM EDT

16.06.2026

Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results

– Orders reinforce strong demand outlook in global health markets and supports 2026 revenue and profitability targets

01.05.2026

Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations

- Appointment supports revenue quality and profitability momentum as the Company activates its transformed operating base - Company announces further operational progress in its Comprehensive Transformation Plan - Company publishes Q4 2025 financial results with revenue broadly in line with previously issued trading update & year-on-year gross margin percentage improvements DUBLIN, May 01, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ: TRIB) (“Trinity” or the “Company”), a commercial‑stage diagnostics and health technology company, today announced the appointment of Jerry Lydon as Head of North America Commercial Operations. Mr. Lydon's appointment represents a deliberate next step as the Company's core diagnostics business transitions from the execution phase of its Comprehensive Transformation Plan toward a sustained focus on building revenue momentum and, importantly, driving profitability from a more efficient and disciplined operating base.

23.03.2026

Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test

DUBLIN and NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a global diagnostics company, today announced successful results from a clinical study of a new, enhanced version of its EpiCapture™ prostate cancer test, engineered to deliver higher precision risk prediction of aggressive prostate cancer.

18.03.2026

Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome

DUBLIN and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into a collaboration agreement with the University at Buffalo, New York (“UB”). The partnership focuses on advancing and commercializing a suite of proprietary biomarkers for the earlier and more accurate detection of Sjögren's Syndrome, one of the most common but underdiagnosed autoimmune diseases.

12.03.2026

Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System

Company begins roll out of innovative diabetes care HbA1c column system in Brazil Commercial leadership strengthened with key appointment DUBLIN, March 12, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has commenced the commercial rollout in Brazil of its updated laboratory blood glucose monitoring solution, the next‑generation HbA1c column system for its Premier Hb9210™ platform, following receipt of local regulatory approval. This approval enables the introduction of the Company's upgraded boronate affinity column system into one of the world's largest diabetes markets.

11.03.2026

Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program

DUBLIN and WILSONVILLE, Ore., March 11, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that senior members of its executive leadership team will attend the ATTD 2026 (Advanced Technologies & Treatments for Diabetes) conference in Barcelona this week to progress strategic collaborations and commercialization plans for the Company's next‑generation Continuous Glucose Monitoring (“CGM”) platform, CGM+.

10.03.2026

Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform

- Clinical trial results support progression of CGM+ toward regulatory submissions and scaled commercialization - Anticipating initiation of pivotal clinical trial in 2026 - Updated electronics architecture delivers significant improvement in glucose measurement accuracy, with a material reduction in MARD across multi-day wear - Multimodal sensing platform powered by advanced AI-native analytics to deliver personalized metabolic health insights - CGM+ next-generation modular device architecture designed to reduce cost and improve sustainability versus current market-leading CGMs - Company is positioning device to participate in fast-growing $15bn CGM market and adjacent sectors DUBLIN and WILSONVILLE, Ore., March 10, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a number of significant technical advancements in the development of its next-generation, finger-stick calibration-free Continuous Glucose Monitoring (CGM) system, CGM+, marking a major step toward bringing the technology to global markets.

Videolar

No Data

There is no data to display

Press-relizlar

16.06.2026

Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results

– Orders reinforce strong demand outlook in global health markets and supports 2026 revenue and profitability targets

01.05.2026

Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations

23.03.2026

Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test

18.03.2026

Trinity Biotech plc (TRIB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Trinity Biotech plc (TRIB)

Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results

Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations

Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test

Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome

Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System

Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program

Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform

Videolar

No Data

Press-relizlar

Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results

Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations

Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test

Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome

Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results

Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations

Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test

Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome

Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System

Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program

Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform

Videolar

No Data

Press-relizlar

Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results

Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations

Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test

Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome

Search stocks

Trinity Biotech plc (TRIB)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Trinity Biotech plc (TRIB)

Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results

Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations

Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test

Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome

Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System

Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program

Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform

Videolar

No Data

Press-relizlar

Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results

Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations

Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test

Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome

Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results

Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations

Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test

Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome

Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System

Trinity Biotech Senior Executives to Attend ATTD 2026 to Advance Collaborations Following Strong Progress in CGM Program

Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform

Videolar

No Data

Press-relizlar

Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results

Trinity Biotech Appoints Jerry Lydon to Lead North America Commercial Operations

Trinity Biotech Announces Successful Clinical Results for Its Enhanced EpiCapture™ Prostate Cancer Test

Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome